$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of possible health hazards caused by long-term use of Vigabatrin (Okeda)
2026-02-01 22:25:32
Check Details
Analysis of the effect of mobosetinib (Anvili) in the treatment of EGFR exon 20 insertion mutations
2026-02-01 22:25:32
Check Details
Liver function monitoring indicators and methods during tepotinib (Tuodekang) treatment
2026-02-01 22:25:32
Check Details
Is regorafenib (Belvango) a targeted drug or a chemotherapy drug and its mechanism of action?
2026-02-01 22:25:32
Check Details
The efficacy and changes in blood indicators after taking Pazopanib (Victor) for 2 months
2026-02-01 22:25:32
Check Details
Opicapone dose adjustment principles and individualized treatment plans
2026-02-01 22:25:32
Check Details
Causes and countermeasures for increased creatinine after taking Fenelidone (Kesenda)
2026-02-01 22:25:32
Check Details
The specific effect of rasagiline (Azila) on improving Parkinson’s motor symptoms
2026-02-01 22:25:32
Check Details
The latest marketing trends and market sales of Pralsetinib in 2025
2026-02-01 22:25:32
Check Details
Dosage reference for how many boxes of capmatinib (Touradda) you need to take in a month
2026-02-01 22:25:32
Check Details
Analysis of the main functions, indications and mechanism of action of Leborexan (Davico) tablets
2026-02-01 22:25:32
Check Details
The efficacy performance and matters needing attention during use of Mavakatai (Mefanto)
2026-02-01 22:25:32
Check Details
1
2
...
1972
1973
1974
1975
1976
1977
1978
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
2
From Causes to Treatments—Exploring Medical Breakthroughs
3
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets
4
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
5
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
6
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
7
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope
8
ARID1A Gene: A New Breakthrough in Tumor Immunotherapy, Turning "Cold Tumors" Hot
9
User Agreement
10
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
11
What is the most important information I should know about WELIREG?
12
How to take and store WELIREG